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Major depressive disorder (MDD) is a common mental disorder associated with a signiﬁcant negative impact on quality of life,
morbidity/mortality, and cognitive function. Individuals who suﬀer with MDD display lower serum/plasmatic total antioxidant
potentials and reduced brain GSH levels. Also, F2-isoprostanes circulatory levels are increased in MDD subjects and are correlated
with the severity of depressive symptoms. Urinary excretion of 8-OHdG seems to be higher in patients with MDD compared to
healthycontrols.Despitethefactthatantidepressantdrugshavebeenusedformorethan50years,theirmechanismofactionisstill
not fully understood. This paper examines preclinical (in vitro and animal model) and clinical literature on oxidative/antioxidant
eﬀects associated with antidepressant agents and discusses their potential antioxidant-related eﬀects in the treatment of MDD.
Substantial data support that MDD seems to be accompanied by elevated levels of oxidative stress and that antidepressant
treatments may reduce oxidative stress. These studies suggest that augmentation of antioxidant defences may be one of the
mechanisms underlying the neuroprotective eﬀects of antidepressants in the treatment of MDD.
1.Introduction
Despite the fact that antidepressant drugs have been used
for more than 50 years, their mechanism of action is still
not fully understood. The hypothesis that antidepressants
restore noradrenergic and serotoninergic neurotransmitter
systems has been dominant [1]. Recently, a new concept of
antidepressants action has been suggested, based on growing
evidence demonstrating antioxidant eﬀects of antidepres-
sants in the treatment of major depressive disorder (MDD)
(Table 1). This paper examines preclinical (in vitro and ani-
mal models) and clinical literature on oxidative/antioxidant
eﬀects of antidepressant agents and discusses the relevance
of intracellular oxidative pathways in the pathophysiology of
MDD.
2. OxidativeStress and
Antioxidants:Background
Reactive oxygen species (ROS) are continuously gener-
ated in physiological conditions and are eﬀectively con-
trolled/eliminated by intracellular and extracellular antiox-
idant systems [2]. ROS are products of normal cellular
metabolism and are well recognized for their dual role as
deleterious and essential compounds, given that ROS can be
harmful or beneﬁcial [3]. Beneﬁcial eﬀects of ROS occur at
low levels and involve cell signalling and signal transduction
[4]. ROS also play an essential role in the human immune
system helping killing and eliminating infectious organisms.
However, elevated or chronic inﬂammations are major
determinants of disease later in the human lifespan, and ROS2 Oxidative Medicine and Cellular Longevity
Table 1: Antioxidant eﬀects of antidepressant agents: preclinical
and clinical studies.
Antidepressant Oxidative/Antioxidant-related eﬀects Drug class
In vitro Animal models Human data
Amitriptyline + + TCA
Bupropion + NDRI
Citalopram + SSRI
Desipramine + TCA
Duloxetine SNRI
Escitalopram + + SSRI
Fluoxetine + + + SSRI
Fluvoxamine + + SSRI
Imipramine + + TCA
Maprotiline + TCA
Milnacipran + SNRI
Mirtazapine + NaSSA
Moclobemide + MAOI
Nefazodone + SNDRI
Nortriptyline + TCA
Paroxetine + SSRI
Reboxetine + + NRI
Sertraline + SSRI
Tianeptine + SSRE
Trazodone + SARI
Venlafaxine + + SNRI
MAOI: monoamine oxidase inhibitor; NaSSA: noradrenergic and speciﬁc
serotonergic antidepressant; NDRI: norepinephrine-dopamine reuptake
inhibitor; NRI: norepinephrine reuptake inhibitor; SARI: serotonin antag-
onist and reuptake inhibitor; SNDRI: serotonin-norepinephrine-dopamine
reuptake inhibitor; SNRI: serotonin-norepinephrine reuptake inhibitor;
SSRE: selective serotonin reuptake enhancer; SSRI: selective serotonin
reuptake inhibitor; TCA: tricyclic or tetracyclic antidepressant.
play a critical role in several age-related diseases, particularly
cancer, cardiac and neurodegenerative disorders [5]. The
major source of ROS in humans is the leakage of superoxide
anion (O2
•−) from mitochondria during oxidative phospho-
rylation. Another minor source of ROS is cytoplasmatic,
including the O2
•−generating enzymes such as xanthine
oxidase (XO), NADPH oxidases, and cytochromes P450
(CytP450). The main ROS include O2
•−,h y d r o g e np e r o x i d e
(H2O2),andhydroxylradical(OH•).OH• isastrongoxidant
formedduringFenton(Fe2+ +H 2O2 → Fe3+ +OH • +OH −)
and Haber-Weiss (H2O2 +O H • → H2O+O 2
•−+H + and
H2O2 +O 2
•− → O2 +O H − +O H •) reactions. Additionally,
some nitrogen species can be potentially dangerous to the
cell, such as peroxynitrite (ONOO–), which is formed in a
rapid reaction between O2
•− and nitric oxide (NO) [3].
The main enzymatic antioxidant defences include super-
oxide dismutase (SOD), catalase (CAT), and glutathione
peroxidase (GPx). SOD enzymes are highly eﬃcient in the
catalyticdismutationofO2
•− andgenerationofH2O2 which,
in turn, can be removed by two types of enzymes—the
catalases(CAT)andperoxidases(e.g.,GPx).Importantly,the
activity of GPx is closely dependent on glutathione reductase
(GR), glutathione tripeptide (GSH), and others cofactors.
Moreover, virtually all cells contain nonenzymatic defenses,
like GSH, vitamins C (ascorbate) and E (alpha-tocopherol),
and metal-binding and related protective proteins [37].
The term “oxidative stress” has been deﬁned as an
imbalance between the generation of ROS and antioxidant
defenses, favouring the former [3]. In situations of oxidative
stress, several biomolecules (e.g., lipid membrane, proteins,
and DNA) can be damaged. Because ROS have extremely
short half-lives, they are diﬃcult to measure. Therefore,
most studies measure products of the damage induced
by oxidative stress. For instance, malondialdehyde (MDA)
is one of the low-molecular-weight end products formed
via the decomposition of primary and secondary lipid
peroxidation products [38]. MDA and other thiobarbituric
reactive substances (TBARS) condense with two equivalents
of thiobarbituric acid that can be assayed spectrophoto-
metrically [39]. Another compound commonly used as a
biomarker of oxidative stress is 4-Hydroxynonenal (4-HNE).
4-HNE is generated in the oxidation of lipids containing
polyunsaturated omega-6 acyl groups, such as arachidonic
or linoleic groups, and the corresponding fatty acids [40].
Perhaps the most accurate markers of lipid peroxidation
are the isoprostanes (i.e., F2-isoprostanes). Isoprostanes are
prostaglandin-like compounds formed in vivo from the free
radical-catalyzed peroxidation of essential fatty acids (pri-
marily arachidonic acid) [41]. Proteins are possibly the most
immediate targets of cellular oxidative damage. Carbonyl
groups (aldehydes and ketones) are produced in protein side
chains (especially of Pro, Arg, Lys, and Thr) when they are
oxidized, which can be measured by speciﬁc techniques [42].
Another method to evaluate levels of oxidation/reduction
content in biological samples is the total reduced thiol
(–SH) quantiﬁcation [43]. ROS can also attack and damage
the DNA, thereby generating 8-hydroxydeoxyguanosine (8-
oxodG) and 8-hydroxyguanosine (8-oxoG) [37].
Additionally, total antioxidant potentials can be mea-
sured using various methods such as TAC, total antioxi-
dant capacity; TRAP, total-radical nonenzymatic antioxidant
potential; OSI, oxidative stress index; TOS, total oxidant
status. Low total antioxidant capacity could be indicative
of oxidative stress or increased susceptibility to oxidative
damage [44].
3. OxidativeStress in Major
DepressiveDisorder
MDD is one of the most common mental disorders among
humansanditisassociatedwithasigniﬁcantnegativeimpact
on quality of life, morbidity/mortality, and cognitive func-
tion.Thepathophysiologyofdepressionismultifactorialand
includeschangesinbrainmonoaminergictransmission(e.g.,
5-HT, NE, DA), abnormalities in neurotransmitter receptors
function (e.g., AC-cAMP pathway), reduced neurotrophic
factors (e.g., BDNF), dysregulation of HPA axis (cortisol),
increasedproinﬂammatorycytokines(e.g.,IL-6,TNF-α,NF -
κB), increased NO (e.g., L-arginine-NO-cGMP pathway),
and increased oxidative stress (e.g., lipid and DNA damage)
[45–47].Oxidative Medicine and Cellular Longevity 3
Individuals who suﬀer with MDD display lower serum/
plasmatic total antioxidant potentials [28, 32, 48]a n d
reduced brain GSH levels [31]a sc o m p a r e dt om a t c h e d
controls.PlasmaticcoenzymeQ10(CoQ10),astrongantiox-
idant and a key molecule in the mitochondrial electron
transport chain, is signiﬁcantly lower in major depressive
patients [34], which indicates lower antioxidant defenses
against oxidative stress. Moreover, increased serum XO levels
observed in MDD subjects suggest increased systemic ROS
production [29]. XO is a widely distributed enzyme involved
in later stages of purine catabolism, which catalyzes the
oxidation of hypoxanthine to xanthine and of xanthine to
uric acid, both reactions with potential to generate O2
•− and
H2O2 [49]. A recent post-mortem study found increased XO
activity in the thalamusand putamen patients with recurrent
MDD [35].
Dimopoulos et al. (2008) have found that F2-isopros-
tanes (F2-iso) circulatory levels were increased in major
depressive patients and were signiﬁcantly correlated with
the severity of depressive symptoms [50]. The presence of
detectable quantities of F2-iso in human biological ﬂuids
implies ongoing lipid peroxidation [51]. Furthermore, uri-
nary excretion of 8-OHdG, a marker of oxidative damage to
DNA, was found to be higher in patients with MDD than
healthy controls [52].
4. AntioxidantEffects of Antidepressants
4.1. Studies In Vitro. The main ﬁndings of in vitro assays
using rat mitochondria and cell culture protocols are
depicted in Table 2. Kolla et al. (2005) have demonstrated
that pretreatment with amitriptyline and ﬂuoxetine protects
against oxidative stress-induced damage in rat pheochro-
mocytoma (PC12) cells. Both drugs attenuated the decrease
in cell viability induced by H2O2 in PC12 cells. Also, pre-
treatment with amitriptyline and ﬂuoxetine was associated
with increased SOD activity, and no signs of cell death
were observed in the treated cells [10]. In another study,
pretreatment with imipramine, ﬂuvoxamine, or reboxetine
inhibited NO production in a dose-dependent manner in an
activated microglia cell culture protocol [11]. The authors
suggested that these antidepressant drugs have inhibitory
eﬀects on IFN-γ-activated microglia and that these eﬀects
are, at least in part, mediated by cAMP-dependent PKA
pathway.
Schmidt et al. (2008) examined the eﬀects of desipram-
ine, imipramine, maprotiline and mirtazapine on mRNA
levels of various antioxidant enzymes in human monocytic
U-937 cells [12]. In this study, short-term treatment with
these drugs decreased mRNA levels of SOD and CAT.
However, long-term treatment increased mRNA levels of
SOD, GST, and GR. These results suggest that the eﬀects
of these antidepressants on the expression of antioxidant
enzymes are dependent on the duration of the treatment
regimen. Zhang et al. (2008) showed for nortriptyline some
antioxidant eﬀects using isolated rat liver mitochondria or
PCN cell culture. Nortriptyline was able to inhibit loss of
mitochondrial membrane potential and the activation of
caspase 3 in isolated rat liver mitochondria and decrease cell
death induced by oxygen/glucose deprivation on PCN cells
[9].
The antioxidant eﬀects of ﬂuoxetine on isolated rat
brain and liver mitochondria have been extensively studied.
Curti et al. (1999) reported that ﬂuoxetine can indirectly and
nonspeciﬁcally aﬀect electron transport and F1F0-ATPase
activity, thereby inhibiting oxidative phosphorylation in
rat brain [6]. Two studies that evaluated the eﬀects of
ﬂuoxetine in rat liver mitochondria revealed mixed results.
Souza et al. (1994) reported that ﬂuoxetine may be poten-
tially hepatotoxic at high doses [7]. However, Nahon et al.
(2005) demonstrated that ﬂuoxetine was able to inhibit the
openingofthemitochondrialpermeabilitytransition(MPT)
pore, the release of cytochrome c (cytC) and protected
against staurosporine-induced apoptotic cell death [8]. An
important diﬀerence between these two studies is the fact
that Souza et al. used isolated liver mitochondria and tested
ﬂuoxetine at diﬀerent concentrations in order to establish
potential toxic doses. On the other hand, Nahon et al. chal-
lenged isolated mitochondria against staurosporine-induced
damage and showed protective eﬀects of ﬂuoxetine in this
model.
In summary, studies in vitro not only revealed
antioxidant-related eﬀects for antidepressant drugs, but
also some potential prooxidant eﬀects speciﬁcally in rat
liver with ﬂuoxetine at higher dosages. Cell culture and
isolated tissues studies are used extensively in research and
drug development; however, these techniques have some
limitations and studies using live organisms (i.e., rodents)
are necessary to better evaluate safety as well as behavioural
eﬀects.
4.2. Animal Models. Several animal model protocols have
been used to investigate oxidative/antioxidant-related eﬀects
of antidepressant drugs. Table 3 summarizes the studies
conducted with acute and chronic antidepressant treatments
in control and stressed animals.
R´ eus et al. (2010) reported increased SOD and CAT
activity and decreased lipid and protein damage in male
rat prefrontal cortex and hippocampus after both acute
and chronic treatment with imipramine [17]. Additionally,
imipramine treatment increased brain creatine kinase and
increased activity of mitochondrial respiratory chain com-
plexes [18, 53]. Katyare and Rajan (1995) showed that long-
term administration of imipramine to female rats resulted
in signiﬁcant stimulation of the states 3 and 4 respiration
rates. This eﬀect was evident within a week of imipramine
administration and was sustained through the second week
of treatment [20]. These results suggest that imipramine
treatmentmayinducechangesinsubstrateoxidationpattern,
increase rate of ATP synthesis, and can potentially increase
mitochondrial ROS production.
Xu et al. (2003) examined dose-dependent eﬀects of
amitriptyline and venlafaxine on neuroprotective proteins in
male rats. In this study, low dose (5mg/kg) of amitriptyline
and venlafaxine increased the intensity of BDNF immunos-
taining in hippocampal pyramidal neurons and the intensity
of Bcl-2 immunostaining in hippocampal mossy ﬁbers,
but did not alter the Cu/Zn-SOD immunoreactivity. High4 Oxidative Medicine and Cellular Longevity
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dose (10mg/kg) of venlafaxine, however, decreased the
intensity of BDNF immunostaining in all subareas of the
hippocampus and increased the intensity of Cu/Zn-SOD
immunostaining in the dentate granular cell layer [21].
More recently, Abdel-Wahab and Salama (2011) showed that
long-term venlafaxine treatment at eﬀective antidepressant
dosages can protect against stress-induced oxidative cellular
and DNA damage in male mice. At all doses tested, venlafax-
ine decreased MDA and total nitrite levels, increased total
antioxidant potential and GSH content, and restored GST
activity in hippocampus of stressed animals. Venlafaxine
also promoted increased total antioxidant potential and
GSH levels in the control, nonstressed group. Finally, this
treatment was able to reduce serum and hippocampal levels
of 8-OHdG (a marker of DNA damage) in stressed animals
[26] showing potential antioxidant eﬀects related to these
antidepressant agents.
The eﬀects of chronic (one month) ﬂuoxetine treat-
ment on lipid and protein oxidative damage, uric acid
concentration in the liver and the activity of transaminases
and transferases in the serum have been investigated in
male rats. Chronic ﬂuoxetine treatment increased the levels
of TBARS, carbonyl groups, and the uric acid content
in the liver. The activities of alanine transaminase (ALT),
aspartate transaminase (AST), and GST were increased in
the serum. The overall eﬀects are more pronounced in
the higher dose (24 versus 8mg/kg) [22]. More recently,
Djordjevic et al. (2011) showed altered antioxidant status
and increased apoptotic signalling in male rat liver after 21
days of ﬂuoxetine treatment. Control animals and stressed
animals displayed decreased activity of SOD and increased
activity of GPx. In addition, in both experimental groups,
ﬂuoxetine altered several markers of apoptosis in the liver,
including decreased Bcl-2 expression and increased DNA
fragmentation [25]. These eﬀects seemed to be associated
with liver toxicity induced by high-dose ﬂuoxetine treatment
in rats.
Novio et al. (2011) investigated the eﬀects of ﬂuox-
etine on intracellular redox status in peripheral blood
cells obtained from male mice exposed to restraint stress.
They found that restraint stress signiﬁcantly increased the
generation of ROS in the peripheral blood and that acute
treatment with ﬂuoxetine partially reversed this eﬀect,
possibly through normalization of SOD and CAT activity
and GSH content [23]. Using a depression-like rat model,
Zaﬁr et al. (2009) examined antioxidant eﬀects of ﬂuoxetine
and venlafaxine in the rat brain. The results evidenced a
signiﬁcant recovery in the activities of SOD, CAT, GST,
GR, and GSH levels by these antidepressants after restraint
stress. Also, ﬂuoxetine and venlafaxine treatment prevented
lipid and protein oxidative damage induced by stress [24].
In another study, acute ﬂuoxetine treatment reduced GPx
activity in the hippocampus, whereas chronic treatment
increased GSH in both hippocampus and prefrontal cortex
of female mice [19].
Recent data support that some antidepressants are able
to modulate NO synthesis and nitrosative stress-associated
signallingcascades.DhirandKulkarni(2007)testeddiﬀerent
dosages of bupropion in male rats. The antidepressant-like
eﬀect of bupropion was prevented by pretreatment with L-
arginine (a substrate of nitric oxide synthase, NOS). Pre-
treatment with 7-nitroindazole (a speciﬁc neuronal NO syn-
thase, nNOS inhibitor) potentiated bupropion’s eﬀects. In
addition, treatment with methylene blue (a direct inhibitor
of NOS and soluble guanylate cyclase, sGC) potentiated the
eﬀect of the drug in the forced swim test [13]. This study
suggests that bupropion possesses antidepressant-like activ-
ities in diﬀerent animal models possibly through dopamin-
ergic and L-arginine-NO-cyclic guanosine monophosphate
(cGMP) signaling pathways. This is consistent with a study
by Zomkowski et al. (2010) showing similar eﬀects with
escitalopram in female mice. The antidepressant-like eﬀect
of escitalopram in the forced swim test (FST) was prevented
by pretreatment with N-methyl-D-aspartic acid (NMDA),
L-arginine, and sildenaﬁl (a phosphodiesterase inhibitor).
Also, the administration of 7-nitroindazole, methylene blue
or ODQ (i.c.v., a soluble sGC inhibitor) in combination
with escitalopram reduced the immobility time in the FST.
This study highlights the role of NMDA receptors and L-
arginine-NO-cGMP pathway in the mechanism of action
of antidepressant agents [14]. Recently, Krass et al. (2011)
reported that imipramine decreased brain nitrite + nitrate
(NO2 +N O 3) levels, a marker of nitrosative stress, in male
rat brain. This result supports the idea that antidepressants
are able to inhibit NO synthesis in the rat brain [16], an
eﬀect that could be mechanistically related to the ability
of L-arginine to counteract their antidepressant-like eﬀects
[15]. In summary, studies in animal models suggest that
antidepressant agents modulate antioxidant enzyme activi-
ties and decrease oxidative stress markers on liver, brain, and
peripheral tissues. In addition, there is a clear association
between high dosages of antidepressants and increased
hepatic oxidative stress. However, a major limitation of the
studies above mentioned is that not all studies measured
oxidative stress markers (i.e., MDA, carbonyl); therefore,
these prooxidant eﬀects need further investigation.
Consistent with the above-mentioned studies, changes
in the blood/brain antioxidant proﬁle have been associated
with changes in depressive-like behaviour. More speciﬁcally,
it has been demonstrated that some classic antioxidants
induce antidepressant-like eﬀects in rodents. In one study,
treatment with Ginkgo biloba extract (10mg/kg) reduced
recorded immobility time in the forced swimming test (FST)
to the same extent as imipramine (39% versus 38%). No
diﬀerences in locomotor activity were observed, suggesting
a selective antidepressant-like eﬀect. This antidepressant-
like eﬀect of Ginkgo biloba extract was associated with
a reduction in lipid peroxidation and superoxide radical
production (as indicated by a downregulation of SOD
activity) [54]. In rats displaying depressive-like behaviour
induced by chronic mild stress, administration of liquiritin,
an antioxidant derived from Glycyrrhiza uralensis, decreased
immobility time, increased sucrose consumption, increased
SODactivity,andattenuatedMDAproductionintheperiph-
eral blood [55]. These ﬁndings are further corroborated by a
study showing that Ebselen (2-phenyl-1,2-benzisoselenazol-
3[2H]-one), a substance that mimics the activity of the
antioxidant enzyme GPx [56], decreased immobility time8 Oxidative Medicine and Cellular Longevity
in rodents, an eﬀect that was dependent on its interaction
with the noradrenergic and dopaminergic systems [57].
Additionally, alpha-tocopherol (vitamin E) administration
produced antidepressant-like eﬀects in animal models of
depression. Along with antidepressant-like eﬀects, long-
term treatment with alpha-tocopherol enhanced antioxidant
defences in the mouse hippocampus and prefrontal cortex,
two structures closely implicated in the pathophysiology of
depression [19].
4.3. Post-Mortem Studies. An u m b e ro fpost-mortem studies
reported altered oxidative stress parameters in individuals
with MDD (Table 4). Michel et al. (2010) showed increased
XO activity in the thalamus and putamen of seven indi-
viduals with an ante-mortem diagnosis of recurrent MDD
(age range= 61–93y.o.). Four of these subjects received SSRI
and one was medicated with clomipramine in the 6 months
before death, while two of them were not antidepressant
treatments[35].TheseresultssuggestincreasedROSproduc-
tion in brain samples of depressive patients due to increased
XO activity. Two recent studies showed reduced oxidized
and total GSH in the prefrontal cortex of MDD subjects as
compared to controls [31, 36]. In addition, GPx levels were
reduced in MDD subjects [31]. Because 10 in 14 patients
have taken antidepressants at time of death, we can speculate
that antidepressants had limited or no eﬀects on GSH and
GPx levels. In a subsequent study with the same cohort, GST
levels were also reduced in MDD patients and no eﬀects of
antidepressant treatment were observed [36].
In summary, while some changes in antioxidant enzymes
have been observed in MDD, these post-mortem studies are
not conclusive mostly because of small sample sizes, lack
of control groups, and lack of relevant information (i.e.,
treatment duration, speciﬁc drugs used).
5.ClinicalData:HumanStudies
In the last decade, an increasing number of studies have
addressed the potential eﬀects of antidepressant treatments
on oxidative stress and antioxidant potential in humans
(Table 4). Corroborating with animal data, the majority of
these studies revealed that antidepressant agents possess
antioxidant properties when used in the treatment of MDD.
I n c r e a s e ds e r u mS O Da n dM D Al e v e l sh a v eb e e nf o u n di n
a cohort of 62 major depressive patients (age 43.8 ± 12.9,
mean±SD; 34/28, female/male ratio) [27]. In another study,
plasmatic vitC levels were reduced in patients with MDD
compared with age- and sex-matched healthy volunteers
(n = 40). Oxidative stress markers (SOD, vitC, lipid
peroxidation) were reversed after 4 weeks of treatment with
ﬂuoxetine (20mg/day, n = 32) and citalopram (20mg/day,
n = 30). Notably, these antioxidant eﬀects were persistent
after 12 weeks of treatment [27].
Bilici et al. (2001) reported increased oxidative stress
in major depressive patients (n = 32), indexed by higher
antioxidant enzyme activities (erythrocyte SOD, GPx, and
plasmatic GR) and MDA levels (erythrocyte and plasmatic).
After treatment with four diﬀerent SSRIs drugs (ﬂuoxetine
20mg/day, n = 7; sertraline 50mg/day, n = 13; ﬂuvoxamine
100mg/day, n = 5; or citalopram 20mg/day, n = 5),
for 12 weeks, antioxidant enzyme activities (plasmatic GPx)
and MDA levels (plasma and erythrocyte) were restored
to control levels. Plasmatic GR and erythrocyte SOD were
also signiﬁcantly decreased in MD patients after 12-week
antidepressant treatment [30]. In another study, a group of
50 MDD patients (age 36.7 ± 5.2; 22/28F/M ratio) who had
achieved remission from their ﬁrst episode of depression
after 3 months of treatment with 20mg of ﬂuoxetine were
tested before and after remission [48]. Before treatment,
MDDpatientsdisplayedincreasederythrocyteSODandCAT
activities, increased MDA levels, and decreased plasmatic
total antioxidant status (TAS) level. After three months of
ﬂuoxetine treatment, MDA levels were normalized [48].
Decreased serum SOD and increased XO were found in 20
individuals with MDD (age range 17–62 years, 19/17 F/M
ratio) [29]. Although increased XO levels indicate increased
free radical production, no diﬀerence was observed in serum
total nitrite levels (a marker of nitrosative stress, possible
associated to ONOO–) between control and MDD patients
before treatment. Also, the authors did not ﬁnd a signiﬁcant
relationship between the duration of illness and SOD, XO
activities, or nitrite levels in this cohort. Treatment with
citalopram (20mg/day, n = 10), ﬂuoxetine (20mg/day,
n = 11), ﬂuvoxamine (150mg/day, n = 7), or sertraline
(50mg/day, n = 8) for 8 weeks increased SOD activity
whereas decreased XO levels suggesting that normalization
of these enzymes was associated with symptomatic improve-
ment [29].
Cumurcu et al. (2009) investigated whether 3 diﬀerent
totalantioxidantparameters(TAC,TOS,andOSI)wereasso-
ciated with MDD and evaluated the impact of antidepressant
treatment on these oxidative/antioxidant parameters in a
cohort of 57 major depressive patients (age 35.5±12.1, 46/11
F/M ratio). TOS and OSI were higher and TAC level was
lower in the MDD group compared with controls (n =
40). Furthermore, the authors found a positive correlation
between the severity of the disease and serum TOS and
OSI (r = 0.58, and r = 0.63, resp.). Also, a negative
correlation was found between the severity of the disease and
serum TAC (r =− 0.553) at the pretreatment stage. After
3 months of treatment with escitalopram, 10–20mg/day,
n = 10; paroxetine, 20–40mg/day, n = 20; or sertraline,
50–100mg/day, n = 27, TOS and OSI were decreased and
TAC was increased compared with pretreatment values [32].
These further suggest that recovery from a major depressive
episode may be associated with normalization of antioxidant
potential induced by antidepressants.
More recently, a 24-week follow-up study evaluated the
eﬀects of long-term antidepressant treatment on oxida-
tive/antioxidant status in a cohort of 50 MDD subjects
(age 33.1 ± 10.0, 39/11 F/M ratio) [33]. Antidepressant
treatments included venlafaxine (125 ± 43.3mg/day , n =
21), milnacipran (100mg/day, n = 2), paroxetine 25 ±
7.6mg/day , n = 8, escitalopram 16.3 ± 5.2mg/day , n =
8, sertraline 80 ± 27.4mg/day , n = 5, citalopram 33.3 ±
11.5mg/day ,n = 3, ﬂuoxetine 20mg/day, n = 1, tianeptine
37.5mg/day,andmoclobemide600mg/day.PlasmaticMDA,
serum oxidized LDL (OxLDL) levels, and erythrocyte SODOxidative Medicine and Cellular Longevity 9
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activity were increased in MDD patients before treatment,
and MDA levels were positively correlated with the severity
of MDD. After 24-weeks of treatment, MDA and SOD levels
decreased. However, TAC was also found decreased after
24-week treatment with antidepressants, indicating that the
oxidative stress observed in depressed patients was partly
improved during 24 weeks of antidepressant treatment.
Patients on venlafaxine were also compared with patients
on SSRIs in the aspect of oxidative stress parameters in the
follow-up period, but no signiﬁcant diﬀerences were found
[33].
Sarandoletal.(2007)foundthatMDDwasaccompanied
by increased peripheral oxidative stress; however, short-term
antidepressant treatment (6 weeks) did not alter oxida-
tive/antioxidant systems in a cohort of 96 MDD patients (age
40 ± 11, 72/24F/M ratio). In this study, MDD patients had
increased plasmatic MDA levels and increased susceptibility
of red blood cells (RBCs) to oxidation. Also, SOD activity
was increased in patients with MDD, and there was a positive
correlation between the severity of depressive symptoms
and SOD activity (r = 0.419). After 6 weeks of treatment
with venlafaxine 75–150mg/day, sertraline 50mg/day, or
reboxetine 4–8mg/day, these oxidative parameters were not
altered [28].
Maes et al. (2009) investigated plasma concentrations of
CoQ10 in 35 depressed patients (age 42.1 ± 10.5, 20/15F/M
ratio) and 22 sex-, age-matched controls. Plasmatic CoQ10
waslowerindepressedpatientsthancontrols.However,there
was no correlation between plasma CoQ10 and the severity
of illness or the number of depressive episodes. During the
study, part of the depressed patients were on antidepressant
treatment at the time of blood sampling (n = 15), while
the remaining were unmedicated (n = 20). There were
no diﬀerences in plasma CoQ10 between depressed patients
who were taking antidepressants and those without [34].
6. Concluding Remarks
Thispaperexaminedpreclinical(invitroandanimalmodels)
and clinical literature on oxidative/antioxidant eﬀects of
antidepressant agents. Overall, most animal and human data
support that antidepressant drugs exert antioxidant eﬀects
during treatment for MDD.
In vitro and animal studies also suggest that some antide-
pressants may be prooxidant at high doses. The antioxidant
eﬀects of antidepressant drugs seem to vary depending
on the dose, treatment regimen, and duration. Notably,
a number of clinical trials revealed that treatment with
antidepressants can reverse the increased oxidative stress
observed in individuals with MDD. Short-term treatments
(4 to 8 weeks) do not seem to alter antioxidant/oxidative
parameters in MDD patients, whereas longer treatments (12
to 24 weeks) seem to induce robust antioxidant eﬀects.
Overall, the literature reviewed does not support dif-
ferences in antioxidant potential between diﬀerent antide-
pressant agents/classes. However, many of these studies were
short in duration and likely underpowered to address the
question of diﬀerences in antioxidant potential amongst
particular drugs and larger studies are warranted.
Brain imaging studies have suggested that MDD may
be associated with decreased volumes of various brain
regions [58–60]. For instance, MDD subjects have smaller
normalized frontal lobe volumes when compared with the
nondepressed controls after controlling for age, gender and
“total cumulative illness rating scale score” [61]. Presence
of temporal lobe atrophy and moderate-to-severe white
matter lesions can predict occurrence of major depression
during a 5-year followup in a population-based sample of
elderly [62]. Considering that the presence of oxidative (and
nitrosative) stressmay causeneurodegeneration and reduced
neurogenesis [63, 64], the relationship between oxidative
stress and changes in brain structure and function in MDD
is a promising area for future studies.
An important issue in biomarker research is the fact
that peripheral markers may not necessarily correlate with
changes in the central nervous system. For instance, Teyssier
et al. (2011) demonstrated that the expression of oxidative
stress-response genes was not altered in the prefrontal
cortex of individuals with MDD. They concluded that the
pathogenic role of oxidative stress in the neurobiology of
depression could not be inferred from alterations in the
periphery [65]. However, in this post-mortem study all of the
patients had received antidepressant treatment, which may
have normalized oxidative stress parameters. Furthermore,
there is also evidence suggesting that BDNF, oxidative stress,
and inﬂammation tend to be abnormal among individuals
with multiple mood episodes and correlate with length of
illness [51, 66, 67]. Peripheral biomarkers detected during
acute mood episodes could in fact constitute markers of
disease activity [68]. Studies of peripheral biomarkers in
large randomized, placebo-controlled trials will ultimately
conﬁrm whether or not normalization of oxidative stress
parameters is associated with treatment response.
In conclusion, there is increasing body of evidence
supporting that MDD may be associated with changes
in oxidative stress markers and that antidepressant agents
(especially long-term treatment) may increase antioxidant
defences. It is possible that augmentation of antioxidant
defences may be one of the mechanisms underlying the
neuroprotective eﬀects of antidepressants observed in the
treatment of MDD.
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